AIFF - Firefly Neuroscience Inc Market Capitalization-to-Revenue Ratio
Cyber threats and digital sovereignty are forcing Firefly Neuroscience, Inc (AIFF) to invest in data security, which impacts the company's revenue valuation. The current level of 7.40 reflects the state of this parameter amid steady demand for neurodiagnostics regardless of economic conditions. The environmental footprint is minimized through cloud technologies, creating a stable asset profile on the chart.
Metric breakdowns and analytics for Firefly Neuroscience Inc (AIFF)
- current quotes and average value forecast:
- market capitalization statistics:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Firefly Neuroscience, Inc|AIFF - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Firefly Neuro|AIFF - Company Debts|Debts to Book Value Firefly Neuro|AIFF - Company Long-Term Debt|Short-Term Debt Volume Firefly Neuroscience|Quick Liquidity Indicator fireflyneuro.com
- net income and valuation multiples indicators:
AIFF - Net Profit|Company Profit Forecast Firefly Neuroscience, Inc|AIFF - P/E Multiple|Projected Price to Earnings Ratio Firefly Neuroscience, Inc.|AIFF - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Firefly Neuro|AIFF - Operating profit EBITDA|Net earnings per share for the last 12 months Firefly Neuroscience|AIFF - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months fireflyneuro.com|AIFF - Net earnings per share growth this year|Expected earnings per share trend next year Firefly Neuroscience, Inc
- issuer revenue and sales details:
Fundamental company analysis:AIFF - fireflyneuro.com
Firefly Neuroscience, Inc (AIFF) is implementing AI-driven EEG analysis for high-precision diagnostics of mental disorders, creating significant added value. The P/S ratio measures market capitalization relative to sales volume, allowing for an assessment of the value of each unit of revenue. By analyzing the historical P/S chart, an investor can uncover hidden revenue manipulations by searching for anomalous gaps in the trend. Current values reflect market expectations regarding the scaling pace of this innovative brand.
Competitors of Firefly Neuroscience, Inc
BIIB - Price to Sales|Neurocrine Biosciences, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RGC|AXSM - Price-to-Revenue Ratio|ACAD (ACADIA Corp) - Market Cap to Revenue Ratio|XENE: P/S Multiple|Price to Sales vikingtherapeutics.com (VKTX)|Market Cap to Revenue SUPN|P/S Multiple Catalyst Pharma|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|HRMY (Harmony Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Biohaven Ltd. BHVN|amylyx.com (AMLX) - Price to Sales|TRVI - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Praxis Precision Medicines Inc PRAX|AVXL: P/S Multiple|Market Cap to Revenue CeriBell EEG|PRTA (Prothena Biosciences) - P/S Multiple|Alector Therapeutics (ALEC) - Price-to-Revenue Coefficient|P/S Multiple ANNX|OMER - Price to Sales|Price-to-Revenue Ratio Neurogene Corp NGNE|ACIU: Market Cap to Revenue Ratio|Voyager Therapeutics - P/S Multiple|neumoratx.com (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|Price to Sales Tevogen Bio Holdings Inc. (TVGN)|Market Cap to Revenue ACOG|CGTX: Market Capitalization-to-Revenue Ratio|P/S Multiple IKT|Price-to-Revenue Coefficient cassavasciences.com|Price-to-Revenue Ratio Assertio ASRT|COYA: Market Cap to Revenue Ratio|VistaGen Therapeutics Inc - P/S Multiple|Ovid Therapeutics Inc. (OVID) - Market Cap to Revenue|ABOS: P/S Multiple|cervomed.com (CRVO) - P/S Multiple|ATHE (Alterity Therapeutics Ltd.) - P/S Multiple|Clene Nanomedicine (CLNN) - Price-to-Revenue Coefficient|P/S Multiple PEPG|JUNS: Price-to-Sales Ratio|P/S Multiple RLMD (Relmada Therapeutics)|ANVS (annovisbio.com) - Price-to-Sales Ratio|GRCE - Price-to-Revenue Ratio|KLTO (Klotho Neurosciences Inc) - Market Cap to Revenue Ratio|NRSN: P/S Multiple|Price to Sales Reviva Pharmaceuticals, Inc. (RVPH)|Market Cap to Revenue MTVA|P/S Multiple neuraxis.com|Price-to-Revenue Ratio Helius Medical (HSDT)|PASG (passagebio.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|Minerva (NERV) - Price to Sales|Athira Pharma, Inc. - P/S Multiple|Price-to-Sales Ratio ADXN|ALZN: P/S Multiple|CYCN - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|KTTA: Market Capitalization-to-Revenue Ratio|P/S Multiple CRGT|ATXI - Price to Sales|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|CARA (Cara Therapeutics Inc.) - Price-to-Sales Ratio|CHRO - Price-to-Revenue Ratio|ELYM: Price-to-Revenue Ratio|ITCI (intracellulartherapies.com) - Market Cap to Revenue|Price to Sales longboardpharma.com (LBPH)|Market Cap to Revenue MRNS|NKGN: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio NeuroBo (NRBO)|Sage Therapeutics Inc - Market Cap to Revenue Ratio|P/S Multiple SNPX (Synaptogenix, Inc.)|trevena.com (TRVN) - Price to Sales|VIGL: Market Cap to Revenue|WENA - P/S Multiple|Cerevel (CERE) - Price-to-Revenue Ratio
